Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.620
-0.070 (-4.14%)
At close: Oct 28, 2025, 4:00 PM EDT
1.680
+0.060 (3.70%)
After-hours: Oct 28, 2025, 7:57 PM EDT
Werewolf Therapeutics Employees
Werewolf Therapeutics had 46 employees as of December 31, 2024. The number of employees decreased by 1 or -2.13% compared to the previous year.
Employees
46
Change (1Y)
-1
Growth (1Y)
-2.13%
Revenue / Employee
n/a
Profits / Employee
-$1,590,087
Market Cap
74.08M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46 | -1 | -2.13% |
| Dec 31, 2023 | 47 | 1 | 2.17% |
| Dec 31, 2022 | 46 | 7 | 17.95% |
| Dec 31, 2021 | 39 | 15 | 62.50% |
| Dec 31, 2020 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HOWL News
- 20 days ago - Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - GlobeNewsWire
- 25 days ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewsWire